Skip to main content
SpringerLink
Log in

Anti-TNF Therapies Other Than Infliximab for the Treatment of Pediatric Inflammatory Bowel Disease

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

  • 633 Accesses

Abstract

The cornerstone of inflammatory bowel disease (IBD) therapy for the last 20 years has revolved around biologic agents targeting tumor necrosis factor alpha (TNFα). Since the approval of infliximab as the first anti-TNFα agent to treat Crohn disease (CD) and ulcerative colitis (UC), other agents also targeting TNFα have come to market, including adalimumab, certolizumab, and golimumab. These agents differ in their route of administration as well as antibody structure. In this chapter we will review the clinical efficacy, safety, and future directions for this class of drugs. To date, there are very few randomized controlled trials evaluating the use of anti-TNFα drugs in pediatric IBD; therefore, the majority of the support for their use in pediatric CD and UC comes from observational studies or extrapolation from the adult literature.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019;20(10)

    Google Scholar 

  2. Targownik LE, Tennakoon A, Leung S, Lix LM, Singh H, Bernstein CN. Temporal trends in initiation of therapy with tumor necrosis factor antagonists for patients with inflammatory bowel disease: A population-based analysis. Clin Gastroenterol Hepatol. 2017;15(7):1061–70. e1

    CAS  PubMed  Google Scholar 

  3. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis. 2002;61(Suppl 2):ii70–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Gurram B, Patel AS. Recent advances in understanding and managing pediatric inflammatory bowel disease. F1000Res. 2019;8

    Google Scholar 

  5. Menegatti S, Bianchi E, Rogge L. Anti-TNF therapy in spondyloarthritis and related diseases, impact on the immune system and prediction of treatment responses. Front Immunol. 2019;10:382.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J Biol Chem. 2013;288(38):27059–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143(2):365–74 e2.

    CAS  PubMed  Google Scholar 

  8. Dubinsky MC, Rosh J, Faubion WA Jr, Kierkus J, Ruemmele F, Hyams JS, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2016;22(4):886–93.

    PubMed  Google Scholar 

  9. Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23(3):453–60.

    PubMed  Google Scholar 

  10. Dziechciarz P, Horvath A, Kierkus J. Efficacy and safety of adalimumab for paediatric Crohn’s disease: a systematic review. J Crohns Colitis. 2016;10(10):1237–44.

    PubMed  Google Scholar 

  11. Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M. Mucosal healing in pediatric Crohn’s disease after anti-TNF therapy: a long-term experience at a single center. Eur J Gastroenterol Hepatol. 2014;26(4):458–65.

    CAS  PubMed  Google Scholar 

  12. Volonaki E, Mutalib M, Kiparissi F, Shah N, Lindley KJ, Elawad M. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2015;27(12):1425–8.

    CAS  PubMed  Google Scholar 

  13. Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(4):606–13.

    PubMed  Google Scholar 

  14. Corica D, Romano C. Biological therapy in pediatric inflammatory bowel disease: a systematic review. J Clin Gastroenterol. 2017;51(2):100–10.

    PubMed  Google Scholar 

  15. Aloi M, Bramuzzo M, Arrigo S, Romano C, D’Arcangelo G, Lacorte D, et al. Efficacy and safety of adalimumab in pediatric ulcerative colitis: a real-life experience from the SIGENP-IBD registry. J Pediatr Gastroenterol Nutr. 2018;66(6):920–5.

    CAS  PubMed  Google Scholar 

  16. Cozijnsen M, Duif V, Kokke F, Kindermann A, van Rheenen P, de Meij T, et al. Adalimumab therapy in children with Crohn disease previously treated with infliximab. J Pediatr Gastroenterol Nutr. 2015;60(2):205–10.

    CAS  PubMed  Google Scholar 

  17. Fumery M, Jacob A, Sarter H, Michaud L, Spyckerelle C, Mouterde O, et al. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(6):744–8.

    CAS  PubMed  Google Scholar 

  18. Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol. 2009;104(12):3042–9.

    CAS  PubMed  Google Scholar 

  19. Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, et al. Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn’s disease. Inflamm Bowel Dis. 2015;21(5):1047–53.

    PubMed  Google Scholar 

  20. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33. quiz 591

    CAS  PubMed  Google Scholar 

  21. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.

    CAS  PubMed  Google Scholar 

  23. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7(3):213–21.

    CAS  PubMed  Google Scholar 

  24. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102–11 e2.

    CAS  PubMed  Google Scholar 

  25. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–38.

    PubMed  Google Scholar 

  26. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7.

    CAS  PubMed  Google Scholar 

  27. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65 e1-3.

    CAS  PubMed  Google Scholar 

  28. Sandborn WJ, Colombel JF, D’Haens G, Van Assche G, Wolf D, Kron M, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37(2):204–13.

    CAS  PubMed  Google Scholar 

  29. Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109(11):1771–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137–47.

    PubMed  PubMed Central  Google Scholar 

  31. Hussain S, Feagan B, A S, Forget S, Sen D, Lacroix B. Use of certolizumab pegol in children and adolescents with active Crohn’s disease: pharmokinetics over 6 weeks in the NUTURE study. Gastroenterology. 2011;Supplement.

    Google Scholar 

  32. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther. 2004;20(11-12):1337–46.

    CAS  PubMed  Google Scholar 

  33. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129(3):807–18.

    CAS  PubMed  Google Scholar 

  34. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38.

    CAS  PubMed  Google Scholar 

  35. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50.

    CAS  PubMed  Google Scholar 

  36. Lichtenstein GR, Thomsen OO, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol. 2010;8(7):600–9.

    CAS  PubMed  Google Scholar 

  37. Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014;40(8):903–16.

    CAS  PubMed  Google Scholar 

  38. Colombel JF, Lemann M, Bouhnik Y, et al. Endoscopic mucosal improvement in patients with active Crohn’s disease treated with certolizumab pegol: week 10 and 54 results of the MUSIC trial. Gastroenterology. 2010;138:166.

    Google Scholar 

  39. Sandborn WJ, Abreu MT, D’Haens G, Colombel JF, Vermeire S, Mitchev K, et al. Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8(8):688–95 e2.

    CAS  PubMed  Google Scholar 

  40. Lim H, Lee SH, Lee HT, Lee JU, Son JY, Shin W, et al. Structural biology of the TNFalpha antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci. 2018;19(3)

    Google Scholar 

  41. Hyams JS, Chan D, Adedokun OJ, Padgett L, Turner D, Griffiths A, et al. Subcutaneous golimumab in pediatric ulcerative colitis: pharmacokinetics and clinical benefit. Inflamm Bowel Dis. 2017;23(12):2227–37.

    PubMed  Google Scholar 

  42. Xu Y, Adedokun OJ, Chan D, Hu C, Xu Z, Strauss RS, et al. Population pharmacokinetics and exposure-response modeling analyses of golimumab in children with moderately to severely active ulcerative colitis. J Clin Pharmacol. 2019;59(4):590–604.

    CAS  PubMed  Google Scholar 

  43. Hyams JS, O’Brien C, Lakshmi P, Rosh J, Turner D, Veereman G, et al. Maintenance golimumab treatment in pediatric UC patients with moderately to severely active UC: PURSUIT PEDS PK long-term study results. Crohn’s Colitis 360. 2020;2(4)

    Google Scholar 

  44. Merras-Salmio L, Kolho KL. Golimumab therapy in six patients with severe pediatric onset Crohn disease. J Pediatr Gastroenterol Nutr. 2016;63(3):344–7.

    CAS  PubMed  Google Scholar 

  45. Pichler J, Memaran N, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Golimumab in adolescents with Crohn’s disease refractory to previous tumour necrosis factor antibody. Acta Paediatr. 2020;

    Google Scholar 

  46. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95; quiz e14-5.

    CAS  PubMed  Google Scholar 

  47. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109 e1.

    CAS  PubMed  Google Scholar 

  48. Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2017;17(7):879–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Cornillie F, Flamant M, Haas T, Jorgensen E, Schirbel A, et al. P239 real-life clinical and quality of life outcomes collected remotely from patients with moderate to severe active ulcerative colitis during induction treatment with golimumab in GO OBSERVE. J Crohn’s Colitis’. 2019;13:S216–S7.

    Google Scholar 

  50. Cunningham G, Samaan MA, Irving PM. Golimumab in the treatment of ulcerative colitis. Ther Adv Gastroenterol. 2019;12:1756284818821266.

    Google Scholar 

  51. Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, et al. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (golimumab: a phase 4, UK, open label, single arm study on its utilization and impact in ulcerative colitis). BMJ Open Gastroenterol. 2018;5(1):e000212.

    PubMed  PubMed Central  Google Scholar 

  52. Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, et al. Variability in golimumab exposure: a ‘Real-Life’ observational study in active ulcerative colitis. J Crohns Colitis. 2016;10(5):575–81.

    PubMed  PubMed Central  Google Scholar 

  53. Tursi A, Allegretta L, Buccianti N, Della Valle N, Elisei W, Forti G, et al. Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers. J Gastrointestin Liver Dis. 2017;26(3):239–44.

    PubMed  Google Scholar 

  54. Cameron FL, Altowati MA, Rogers P, McGrogan P, Anderson N, Bisset WM, et al. Disease status and pubertal stage predict improved growth in antitumor necrosis factor therapy for pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(1):47–55.

    CAS  PubMed  Google Scholar 

  55. Pichler J, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Growth and bone health in paediatric patients with Crohn’s disease receiving subcutaneous tumor necrosis factor antibody. World J Gastroenterol. 2015;21(21):6613–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Walters TD, Faubion WA, Griffiths AM, Baldassano RN, Escher J, Ruemmele FM, et al. Growth improvement with adalimumab treatment in children with moderately to severely active Crohn’s disease. Inflamm Bowel Dis. 2017;23(6):967–75.

    PubMed  Google Scholar 

  57. Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S, et al. The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn’s disease (CD). J Crohns Colitis. 2012;6(3):337–44.

    CAS  PubMed  Google Scholar 

  58. Veerappan SG, Healy M, Walsh BJ, O’Morain CA, Daly JS, Ryan BM. Adalimumab therapy has a beneficial effect on bone metabolism in patients with Crohn’s disease. Dig Dis Sci. 2015;60(7):2119–29.

    CAS  PubMed  Google Scholar 

  59. Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, et al. Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: results from InspirADA. J Crohns Colitis. 2017;11(11):1317–25.

    PubMed  PubMed Central  Google Scholar 

  60. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103(12):3132–41.

    PubMed  Google Scholar 

  61. Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn’s disease. Am J Gastroenterol. 2009;104(8):1976–83.

    PubMed  Google Scholar 

  62. Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Ther Adv Gastroenterol. 2011;4(6):375–89.

    CAS  Google Scholar 

  63. Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011;33(5):541–50.

    CAS  PubMed  Google Scholar 

  64. Diederen K, de Ridder L, van Rheenen P, Wolters VM, Mearin ML, Damen GM, et al. Complications and disease recurrence after primary ileocecal resection in pediatric Crohn’s disease: a multicenter cohort analysis. Inflamm Bowel Dis. 2017;23(2):272–82.

    PubMed  Google Scholar 

  65. Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol. 2013;108(11):1731–42.

    CAS  PubMed  Google Scholar 

  66. Aguas M, Bastida G, Cerrillo E, Beltran B, Iborra M, Sanchez-Montes C, et al. Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol. 2012;18(32):4391–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Colombel JF, D’Haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020;14(2):254–66.

    PubMed  Google Scholar 

  68. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463–8; quiz e10-1.

    PubMed  Google Scholar 

  69. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(6):978–85.

    PubMed  Google Scholar 

  70. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20(2):231–9.

    PubMed  Google Scholar 

  71. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390(10114):2779–89.

    Google Scholar 

  72. Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2017;8(2):103–13.

    PubMed  PubMed Central  Google Scholar 

  73. Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(2):361–8.

    PubMed  Google Scholar 

  74. Russell RK, Wilson ML, Loganathan S, Bourke B, Kiparissi F, Mahdi G, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(8):946–53.

    CAS  PubMed  Google Scholar 

  75. Nuti F, Viola F, Civitelli F, Alessandri C, Aloi M, Dilillo A, et al. Biological therapy in a pediatric Crohn disease population at a referral center. J Pediatr Gastroenterol Nutr. 2014;58(5):582–7.

    PubMed  Google Scholar 

  76. Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn’s disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2017;45(1):50–62.

    CAS  PubMed  Google Scholar 

  77. Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. J Crohns Colitis. 2016;10(11):1259–66.

    PubMed  Google Scholar 

  78. Grover Z. Combination therapy with dose optimized thiopurine and adalimumab in Crohn’s disease. Inflamm Bowel Dis. 2017;23(9):1566–7.

    PubMed  Google Scholar 

  79. Kariyawasam VC, Ward MG, Blaker PA, Patel KV, Goel R, Sanderson JD, et al. Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Crohn’s disease. Inflamm Bowel Dis. 2017;23(9):1555–65.

    PubMed  Google Scholar 

  80. Frias Gomes C, Colombel JF, Torres J. De-escalation of therapy in inflammatory bowel disease. Curr Gastroenterol Rep. 2018;20(8):35.

    PubMed  Google Scholar 

  81. Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, et al. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2016;14(8):1120–9 e6.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018;48(4):394–409.

    CAS  PubMed  Google Scholar 

  83. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162–75.

    CAS  PubMed  Google Scholar 

  84. Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–302.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Toruner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–26.

    CAS  PubMed  Google Scholar 

  86. Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2010;16(12):2168–72.

    PubMed  Google Scholar 

  87. Kaunitz JD. Paradigm shifts in perspective III: the discovery of tumor necrosis factor. Dig Dis Sci. 2014;59(4):710–1.

    PubMed  PubMed Central  Google Scholar 

  88. Olen O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ. 2017;358:j3951.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443–51; quiz e88-9.

    PubMed  Google Scholar 

  90. Joosse ME, Aardoom MA, Kemos P, Turner D, Wilson DC, Koletzko S, et al. Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN. Aliment Pharmacol Ther. 2018;48(5):523–37.

    CAS  PubMed  Google Scholar 

  91. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41 e1.

    CAS  PubMed  Google Scholar 

  92. Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis. 2013;7(11):853–67.

    PubMed  Google Scholar 

  93. Pirkle SB, Bhattacharjee SB, Reddy SB, Shi LLM, Lee MJM, Dalal SM. Anti-TNF use prior to bowel resection is not associated with 30 day postoperative complications: a national database study. Crohn’s Colitis 360. 2019;1(2):otz012.

    Google Scholar 

  94. Kotze PG, Magro DO, Martinez CAR, Saab B, Saab MP, Pinheiro LV, et al. Adalimumab and postoperative complications of elective intestinal resections in Crohn’s disease: a propensity score case-matched study. Color Dis. 2017;

    Google Scholar 

  95. Coronavirus and IBD Reporting Database; 2020.

    Google Scholar 

  96. Li SJ, Perez-Chada LM, Merola JF. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70–80.

    PubMed  Google Scholar 

  97. Guerra I, Perez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894–901.

    PubMed  Google Scholar 

  98. Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease. Biologics. 2018;12:69–73.

    PubMed  PubMed Central  Google Scholar 

  99. Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-tumor necrosis factor-alpha induced systemic lupus erythematosus(). Open Rheumatol J. 2012;6:315–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44(1):e20–2.

    PubMed  Google Scholar 

  102. Averbukh LD, Wu GY. Role of biologics in the development of autoimmune hepatitis: a review. J Clin Transl Hepatol. 2018;6(4):402–9.

    PubMed  PubMed Central  Google Scholar 

  103. Ricciuto A, Kamath BM, Walters TD, Frost K, Carman N, Church PC, et al. New onset autoimmune hepatitis during anti-tumor necrosis factor-alpha treatment in children. J Pediatr. 2018;194(128-35):e1.

    Google Scholar 

  104. Lucio S. The complexities of biosimilars and the regulatory approval process. Am J Manag Care. 2018;24(11 Suppl):S231–S6.

    PubMed  Google Scholar 

  105. Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017;11:5–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. de Ridder L, Assa A, Bronsky J, Romano C, Russell RK, Afzal NA, et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019;68(1):144–53.

    PubMed  Google Scholar 

  107. Danese S, Gomollon F, Governing B. Operational Board of E. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–9.

    PubMed  Google Scholar 

  108. de Ridder L, Waterman M, Turner D, Bronsky J, Hauer AC, Dias JA, et al. Use of biosimilars in paediatric inflammatory bowel disease: a position statement of the ESPGHAN paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr. 2015;61(4):503–8.

    PubMed  Google Scholar 

  109. Sieczkowska J, Jarzebicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016;10(2):127–32.

    CAS  PubMed  Google Scholar 

  110. Sieczkowska-Golub J, Meglicka M, Plocek A, Banaszkiewicz A, Jarzebicka D, Toporowska-Kowalska E, et al. Induction therapy with biosimilar infliximab in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2017;65(3):285–8.

    CAS  PubMed  Google Scholar 

  111. Richmond L, Curtis L, Garrick V, Rogers P, Wilson M, Tayler R, et al. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2018;103(1):89–91.

    PubMed  Google Scholar 

  112. Wynne C, Altendorfer M, Sonderegger I, Gheyle L, Ellis-Pegler R, Buschke S, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE(R)-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25(12):1361–70.

    CAS  PubMed  Google Scholar 

  113. Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–87.

    CAS  PubMed  Google Scholar 

  114. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76(6):1093–102.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Stephanie Gold & Louis Cohen

Authors
  1. Stephanie Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louis Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louis Cohen .

Editor information

Editors and Affiliations

  1. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Petar Mamula

  2. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Judith R. Kelsen

  3. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Andrew B. Grossman

  4. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Robert N. Baldassano

  5. Division of Pediatric Gastroenterology, Prisma Health Children’s Hospital—Upstate, Greenville, SC, USA

    Jonathan E. Markowitz

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gold, S., Cohen, L. (2023). Anti-TNF Therapies Other Than Infliximab for the Treatment of Pediatric Inflammatory Bowel Disease. In: Mamula, P., Kelsen, J.R., Grossman, A.B., Baldassano, R.N., Markowitz, J.E. (eds) Pediatric Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-14744-9_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14744-9_32

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14743-2

  • Online ISBN: 978-3-031-14744-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation